LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH HIDS (HYPER-IGD SYNDROME) - INTERIM ANALYSIS OF THE RELIANCE REGISTRY

Oommen P, Kallinich T, Rech J, Blank N, Weber-Arden J, Kuemmerle-Deschner JB (2022)

Publication Type: Conference contribution

Publication year: 2022

Journal

Annals of the Rheumatic Diseases BMJ Publishing Group

Publisher: BMJ PUBLISHING GROUP

City/Town: LONDON

Pages Range: 1027-1028

Conference Proceedings Title: ANNALS OF THE RHEUMATIC DISEASES

DOI: 10.1136/annrheumdis-2022-eular.5063

Authors with CRIS profile

Hans Jürgen Rech Department of Medicine 3 – Rheumatology and Immunology

Involved external institutions

Universitätsklinikum Heidelberg DE Germany (DE) Universitätsklinikum Tübingen DE Germany (DE) Charité - Universitätsmedizin Berlin DE Germany (DE) Novartis AG CH Switzerland (CH) Heinrich-Heine-Universität Düsseldorf DE Germany (DE)

How to cite

APA:

Oommen, P., Kallinich, T., Rech, J., Blank, N., Weber-Arden, J., & Kuemmerle-Deschner, J.B. (2022). LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH HIDS (HYPER-IGD SYNDROME) - INTERIM ANALYSIS OF THE RELIANCE REGISTRY. In ANNALS OF THE RHEUMATIC DISEASES (pp. 1027-1028). LONDON: BMJ PUBLISHING GROUP.

MLA:

Oommen, P., et al. "LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH HIDS (HYPER-IGD SYNDROME) - INTERIM ANALYSIS OF THE RELIANCE REGISTRY." Proceedings of the ANNALS OF THE RHEUMATIC DISEASES LONDON: BMJ PUBLISHING GROUP, 2022. 1027-1028.

BibTeX: Download